Publications by authors named "Paula Aguilera Peiro"
Long-Term Observations on the European Photopatch Test Baseline Series (EPTBS) in Real Clinical Practice: 11 Years of Results in a Spanish Cohort and Suggestions for an EPTBS Update.
Contact Dermatitis
December 2024
Background: The European Photopatch Testing Baseline Series (EPTBS) was published in 2013. However, limited data exist regarding the real-world clinical application of the EPTBS.
Objectives: This study aims to describe the photopatch test experience with the EPTBS over 11 years at a tertiary hospital in Spain.
Successful treatment of facial cutaneous leishmaniasis with photodynamic therapy.
Indian J Dermatol Venereol Leprol
September 2022
Solar capillaritis during hydrochlorothiazide treatment: A case report.
Photodermatol Photoimmunol Photomed
January 2023
Pseudoporphyria-a diagnostic challenge: A case series and a proposed diagnostic algorithm.
Photodermatol Photoimmunol Photomed
November 2022
Article Synopsis
- The study investigates the long-term effectiveness and safety of givosiran in treating acute hepatic porphyria, a condition characterized by toxic levels of heme precursors.
- It involved an interim analysis of the ENVISION study, where patients either received givosiran or a placebo for six months, followed by an open-label extension.
- Results showed that givosiran significantly reduced attack frequency, need for hemin treatment, and daily pain severity, while also improving patients' quality of life with an acceptable safety profile.
Background: Up-regulation of hepatic delta-aminolevulinic acid synthase 1 (ALAS1), with resultant accumulation of delta-aminolevulinic acid (ALA) and porphobilinogen, is central to the pathogenesis of acute attacks and chronic symptoms in acute hepatic porphyria. Givosiran, an RNA interference therapy, inhibits ALAS1 expression.
Methods: In this double-blind, placebo-controlled, phase 3 trial, we randomly assigned symptomatic patients with acute hepatic porphyria to receive either subcutaneous givosiran (2.
Background: Intralesional injection of Candida antigen appears to be an effective alternative for the treatment of warts.
Aim: To determine the efficacy and safety of this treatment.
Methods: We retrospectively reviewed records of all children who received intralesional injection of Candida antigen at our center from January 2008 to July 2013.